Business Context and Reporting Period
This Form 8-K was filed by SeaStar Medical Holding Corporation on December 20, 2023. The report addresses a regulatory event concerning the company's continued listing status on The Nasdaq Capital Market under the trading symbol "ICU".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the Market Value Rule threshold, which requires a market value of listed securities of at least $35.0 million. The company failed to meet this requirement for the applicable period.
Material Changes
- Delisting Notice: The company received a notice from Nasdaq stating it had not regained compliance with Listing Rule 5550(b)(2) due to insufficient market value.
- Appeal Filed: On December 19, 2023, the company submitted a request for a hearing before a Nasdaq Hearing Panel to appeal the delisting determination.
- Stay of Action: Nasdaq has stayed the delisting action pending the final written decision of the Hearing Panel.
Outlook, Risks, and Management Commentary
- Hearing Schedule: A hearing is scheduled to be held on March 12, 2024.
- Trading Status: Subject to the final decision, the company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "ICU" without immediate interruption.
- Risk: The primary risk is the potential delisting of the company's common stock if the Hearing Panel upholds the initial determination.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearing Panel scheduled for March 12, 2024.
- Monitor the company's market capitalization to assess progress toward the $35.0 million threshold.
- Review subsequent filings for any updates on the delisting appeal or alternative compliance plans.